WindMIL Therapeutics Appoints Dr. Kimberly Noonan as Chief Science & Technology Officer
May 06, 2021 07:00 ET | Source: WindMIL Therapeutics WindMIL Therapeutics Philadelphia, Pennsylvania, UNITED STATES
PHILADELPHIA and BALTIMORE, May 06, 2021 (GLOBE NEWSWIRE) WindMIL Therapeutics, a clinical-stage company developing marrow-infiltrating lymphocytes (MILs
®) for cancer immunotherapy, today announced the appointment of Co-Founder Kimberly Noonan, PhD, MPH, to Executive Vice President, Chief Science & Technology Officer. In this role, Dr. Noonan’s leadership will expand to include WindMIL’s efforts in manufacturing and manufacturing science and technology (MS&T).
“As we continue to build momentum developing MILs as a novel class of autologous cell therapies for cancer immunotherapy, we are delighted to broaden Dr. Noonan’s role at WindMIL,” said Don Hayden, Chairman and Chief Executive Officer of WindMIL Therapeutic
THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION 2014/596/EU AS IT FORMS PART OF LAW IN THE UNITED KINGDOM BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018. UPON THE PUBLICATION OF THIS ANNOUNCEMENT, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.
Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for deadly blood diseases, announces its results for the year ended 31 December 2020.
• Demonstrated that HEMO-CAR-T cells are effective against Acute Myloid Leukemia in vitro and in vivo • Developed a novel cell-based platform technology, referred to as CBR, for the treatment of emerging viral diseases, including COVID-19, as well as certain types of cancer
Academic All-State: Top 10 students statewide
Des Moines Register
GPA: 4.0
Major: Economics and Mathematics
What are your life goals? I hope to accomplish two things: enjoy my occupation and provide for my kids the best life that I can. Regarding the first point, I have long since determined that I must find work that I enjoy in order to live a fulfilling life. It can hardly be called living if you spend half of your waking hours doing something that you dread to do. I know what I like to do, so I hope that will make finding enjoyable work a rather straightforward task. In addition, I believe that one can only “make new” or “make a difference” if one enjoys their work. Enjoying and having a passion for what I do will be a critical part of being the best possible version of myself. This leads into my second point regarding the family that I will form. I continue to be inspired everyday by how hard my dad worked to provide for our family. I never realized it when I was you
CARISMA Therapeutics to Present Data at The American Association for Cancer Research Annual Meeting
- First study evaluating CAR-macrophages in fully immunocompetent solid tumor mouse models shows significant tumor control, increased survival, and induction of anti-tumor immunity
- New ultra-rapid, same-day CAR-monocyte manufacturing process may reduce vein-to-vein time
News provided by
Share this article
Share this article
PHILADELPHIA, April 9, 2021 /PRNewswire/ CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced study findings accepted for virtual presentation at The American Association for Cancer Research (AACR) Annual Meeting on Saturday, April 10 – Thursday, April 15. The accepted data reinforces the potential of CARISMA s proprietary chimeric antigen receptor macrophage (CAR-M) platform, as well as the importance of evaluating CAR-monocytes (CAR-Mono) as a novel and exped
University of Pennsylvania Targets Net-Zero by 2050
The $14.9 billion endowment becomes the latest institutional investor to target the goals of the Paris Agreement.
The University of Pennsylvania (Penn)’s $14.9 billion endowment is the latest institutional investor to set the goal of eliminating net greenhouse gas emissions from its investment portfolio by 2050.
The target supports the goals of the 2015 Paris Agreement and the UN’s Intergovernmental Panel on Climate Change (IPCC) of reducing the world’s net emissions caused by human activity to zero by 2050 in order to limit the global warming increase to 1.5° Celsius from pre-industrial levels.
Penn’s Office of Investments, which manages the university’s endowment and pension assets, said it will reach net-zero mainly by eliminating the greenhouse gas emissions associated with the endowment’s underlying investments.